Abstract
AbstractArrhythmogenic right ventricular cardiomyopathy (ARVC) is a fatal genetic heart disease characterized by cardiac arrhythmias, in which fibrofatty deposition leads to heart failure, with no effective treatments. Plakophilin 2 (PKP2) is the most frequently mutated gene in ARVC, and although altered RNA splicing has been implicated, there are no models to study its effect and therapeutics. Here, we generate a mouse model harboring a PKP2 mutation (IVS10-1G>C) affecting RNA splicing, recapitulating ARVC features and sudden death starting at 4 weeks. Administering AAV-PKP2 gene therapy (adeno-associated viral therapy to drive cardiac expression of PKP2) to neonatal mice restored PKP2 protein levels, completely preventing cardiac desmosomal and pathological deficits associated with ARVC, ensuring 100% survival of mice up to 6 months. Late-stage AAV-PKP2 administration rescued desmosomal protein deficits and reduced pathological deficits including improved cardiac function in adult mice, resulting in 100% survival up to 4 months. We suggest that AAV-PKP2 gene therapy holds promise for circumventing ARVC associated with PKP2 mutations, including splice site mutations.
Funder
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
LEXEO Therapeutics Inc.
Additional Ventures, Joe and Clara Tsai Foundation
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Thiene, G., Corrado, D. & Basso, C. Arrhythmogenic right ventricular cardiomyopathy/dysplasia. Orphanet J. Rare Dis. 2, 45 (2007).
2. Sen-Chowdhry, S. et al. Arrhythmogenic cardiomyopathy: etiology, diagnosis, and treatment. Annu. Rev. Med. 61, 233–253 (2010).
3. Mattesi, G. et al. Natural history of arrhythmogenic cardiomyopathy. J. Clin. Med. 9, 878 (2020).
4. Peters, S., Trummel, M. & Meyners, W. Prevalence of right ventricular dysplasia-cardiomyopathy in a non-referral hospital. Int. J. Cardiol. 97, 499–501 (2004).
5. Elias Neto, J. et al. Arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D) - what we have learned after 40 years of the diagnosis of this clinical entity. Arq. Bras. Cardiol. 112, 91–103 (2019).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献